Back to top

earnings-estimates-revisions: Archive

Zacks Equity Research

Here's What Key Metrics Tell Us About Jefferies (JEF) Q4 Earnings

While the top- and bottom-line numbers for Jefferies (JEF) give a sense of how the business performed in the quarter ended November 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Albertsons Companies (ACI) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Albertsons Companies (ACI) give a sense of how its business performed in the quarter ended November 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Compared to Estimates, Constellation Brands (STZ) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for Constellation Brands (STZ) give a sense of how its business performed in the quarter ended November 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

MSC Industrial (MSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for MSC Industrial (MSM) give insight into how the company performed in the quarter ended November 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Gartner (IT) Upgraded to Buy: Here's Why

Gartner (IT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why

Monte Rosa Therapeutics (GLUE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

MSC Industrial (MSM) Moves to Buy: Rationale Behind the Upgrade

MSC Industrial (MSM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

EverQuote (EVER) Upgraded to Strong Buy: Here's Why

EverQuote (EVER) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Ero Copper (ERO) Upgraded to Strong Buy: Here's Why

Ero Copper (ERO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

StepStone Group (STEP) Upgraded to Buy: What Does It Mean for the Stock?

StepStone Group (STEP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).